focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
They are not overdue...read the statement...
All reliant on a third party...and they said it was anticipated.
They NEVER said they will RNS at end of April...if they did they would be late...they didn't so they're not.
Get over it guys...stop going over it time and time again...
8If you bought shares with your own cash you want the SP to go up so will always be drawn to a positive outlook.
If you're shorting you want the SP to tumble so will push a negative agenda.
If you work for a company who receives revenue or pays commission on ad clicks you will want to see lots of scrolling up and down so will push argumentative dialogue and engagement.
Take your pick...p
T
Mmmm...one of his compsnies just completed a RTO by the looks of it...
https://www.aceragen.com/news/idera-pharmaceuticals-announces-name-change-to-aceragen-inc-and-provides-near-term-strategic-outlook/
Could this be a target RTO company for Avacta...? If a Nazdaq listing is being looked at.
Some might find this of interest.
https://www.sharesmagazine.co.uk/article/understanding-the-different-types-of-stock-market-announcements
From my discusdions with one or two AIM listed company FD's...they have said they have a big input into RNSs financial or otherwise.
'The largest deal by far was signed in October 2023 between Daiichi Sankyo and Merck & Co., for co-development and commercialization of three of Daiichi’s oncology-focused antibody–drug conjugate (ADC) candidates: patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan. The deal involved a $4 billion upfront cash payment—unheard of in recent dealmaking—and will see the two big pharma companies collaborating to develop the candidates worldwide, except in Japan where Daiichi will retain rights.'
If they weren't happy with what was happening in the US 2W study they would not have given the go ahead to start recruiting in the UK.
Below is
'The Company announced that patients are now being dosed in a two-weekly dose escalation study with the aim of defining the recommended Phase 2 dose (RP2D), allowing dose expansions to begin in H2 2024 followed by the Phase 2 efficacy study in a selected orphan indication
o Avacta receives approval to enrol patients in the UK in the ongoing two-weekly dose escalation study
o Patients in the two-weekly study in each cohort can be dosed in parallel allowing the Company to remain on track to begin the dose expansion studies in the second half of 2024.'
You guys are just going round in circles for arguments sake...
If it wasn't deemed safe by now they would put a stop to the 2W trial and that wojld have to be RNS'd. Agree with Icecool no neex to say more than they have right now...just get on with the trials in US and UK.
May is a bad time for holidays everywhere...
I see the Indians are back...don't engage...
If you're a tad bored today...here's the fill text...
https://www.sciencedirect.com/science/article/abs/pii/S0223523423010863#:~:text=The%20emergence%20of%20ADCs%20has,effectively%20alleviated%20the%20side%20effects.
'Although ADCs have many advantages, they also face problems such as complex pharmacokinetics, inevitable side effects, and ineffective payloads release [3]. Many of these problems are related to the mAb component. In view of this, one idea to improve targeted therapy is to abandon the structure of traditional mAbs and instead choose to conjugate toxic reagents with CTP with small molecular weights to generate novel targeted therapy drugs, namely PDCs. The mechanism of action of PDCs is shown in Fig. 1.
PDCs targeted cancers are an emerging targeted treatment method and are mainly composed of three parts:'
It's a long time ago but did you know...'Eliot Forster served as Head of Development and Operations for the European Union and Asia at Pfizer Inc. from 1996 to 2007'...
Why did Levicept hire Eliot Foster as their CEO? And who would have made the decision? As I said...you need to look at who was on the Board at the time. Networking, networking, networking...fills board seats of established companies not ads and head hunters...ads and head hunters are used just to meet employment regs.
You are all assuming he was pushed...well maybe as a scientist he just wants to stay close to the lab. Once a compsny goes into commercialisation mode the CEOs job takes on a different focus. Plus the DX side has grown by a huge number of new personnel etc. Maybe he just feels more comfortable with testubes rather than people politics. Maybe he just loves being head of a start up rather than a global to be.
Think it's time to just put it all to bed now...he's gone...he did his job to the best of his ability and now he's moved on...the end.
Pfizer Ventures invests in areas of current or future strategic interest to Pfizer with the goal of remaining at the forefront of life science advances. We identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.'
They are invested in Levicepts and Eliot is their CEO...
Https://www.pfizer.com/und/science/clinical-trials/integrity-and-transparency/stem-cell-research
Coincidence or what.
Avacta signposts European specialist fund invested and now our psrtners on FE are signposting they are in discussions with EU based company builder...
Would be amazing if they were the same company...just got to wait and see...